|
BIOSTEM TECHNOLOGIES INC.
US SYMBOL: BSEM
Last Price: 4.43 | Website | Latest News
Are you ready to revisit a past winner who, since our last alert already delivered up to +115% Gains, yet now presents another opportunity?
And to some of you this one may be a familiar face operating in the MedTech space with cutting-edge regenerative medicine, a GAME-CHANGING acquisition, and a MUST-SEE chart.
The $18+ BILLION advanced wound care market is exploding. An aging population, rising diabetes rates, and the push toward regenerative therapies over traditional treatments are creating a PERFECT STORM for companies in this space.
And today we're bringing you an OTC MedTech company with 97% GROSS MARGINS, clinically PROVEN products, a fresh acquisition that DOUBLES their reach, and a $25.50 ANALYST TARGET suggesting over 475% UPSIDE...
WE ARE ISSUING AN IMMEDIATE ALERT ON BSEM FOR TOMORROW!
BioStem Technologies, Inc. (OTC: BSEM) is a leading regenerative medicine company focused on the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care. Their proprietary BioRetain® processing method preserves the natural growth factors and tissue structure of perinatal tissue - creating products that are clinically proven to deliver SUPERIOR wound healing outcomes.
What makes BSEM exciting RIGHT NOW? Let us count the ways...
In 2024, BSEM posted $301.8 MILLION in revenue, a staggering 1,709% increase from 2023. Yes, you read that right.
In 2025 while the company saw revenue drop due to Centers for Medicare & Medicaid Services (CMS) reimbursement changes in 2025, BSEM didn't sit still. They went on OFFENSE, acquiring BioTissue's surgical and wound care business in January 2026 for ~$15 million, adding the well-known Neox® and Clarix® product lines, a nationwide hospital sales force, and major GPO contracts.
Even the CEO Jason Matuszewski has been BUYING SHARES dropping $100,000 on 15,500 shares in August 2025.
BSEM is firing on ALL cylinders. And it just last week reported Q4/FY2025 earnings reporting net revenue of $10.1 million for the fourth quarter 2025 and gross margin of 97%! Read their full breakdown here.
IS BSEM SETTING UP FOR ANOTHER TRIPLE-DIGIT BREAKOUT?
BSEM has already had a history of rallies, our December alert on BSEM went on to gain up to 115%!
Now the stock appears to have consolidated, and with their recent acquisition of BioTissue, can another breakout be coming?
Keep in mind, Zacks analyst target is $25.50. Do that math. That's over 475% UPSIDE.
THE BOTTOM LINE
Let's recap what we're looking at here...
BSEM posted net revenue of $10.1 million for the fourth quarter 2025 with a gross margin of 97%.
Their CEO is BUYING shares.
They just acquired BioTissue's hospital business for $15M — adding $29M in annual sales and an entirely new market channel. Their clinical trials show their technology is nearly TWICE as likely to achieve lasting wound closures as standard of care. And the stock?
It's sitting around $4.42 with a ~$74M market cap.
Zacks analyst target is $25.50. Do that math. That's over 475% UPSIDE.
With a potential NASDAQ uplisting on the horizon, KPMG auditing the books... traders looking for a MedTech play with real margins, clinical proof, insider conviction, and massive upside potential BSEM needs to be on your radar. NOW.
Make sure you put it on your screen RIGHT NOW and
Follow on Twitter for Updates + Play-by-Play!
|
